News
08-17-2011, 09:50 PM
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."
More... (http://www.news-medical.net/news/20110818/Syndax-receives-European-patent-allowance-for-entinostat-to-treat-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20110818/Syndax-receives-European-patent-allowance-for-entinostat-to-treat-metastatic-breast-cancer.aspx)